scispace - formally typeset
Open AccessJournal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
- Vol. 397, Iss: 10277, pp 881-891
TLDR
The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
About
This article is published in The Lancet.The article was published on 2021-03-06 and is currently open access. It has received 862 citations till now. The article focuses on the topics: Booster dose & Vaccine efficacy.

read more

Citations
More filters
Journal ArticleDOI

Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV

TL;DR: In this paper , the neutralizing antibody (NAb) responses to the third dose of the inactivated COVID-19 vaccine administered to people living with human immunodeficiency virus (HIV; PLWH) with different inoculation intervals.
Posted ContentDOI

First long-term safety analysis of the ChAdOx1-nCoV-19 corona virus vaccine: results from a prospective observational study in priority vaccinated groups in North India

TL;DR: In this paper , the authors provided the one-year safety results of the ChAdOx1-nCoV-19/AZD1222 vaccine and determined risk factors of development of adverse events of special interest (AESIs) as well as persistent AESIs.
Posted ContentDOI

Effectiveness of vaccination in preventing severe SARS CoV-2 infection in South India-a hospital based cross sectional study

TL;DR: In this article, the effectiveness of Covid 19 vaccines in preventing the new and severe SARS CoV-2 infections was investigated in a large-scale study among the 4765 patients consecutive adult inpatients admitted in the Covid19 wards of a tertiary care hospital from May 1,2021 to July 7, 2021 during the second wave of the 2016-2017 SARS Cov-2 pandemic.
References
More filters
Journal ArticleDOI

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 - 
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

TL;DR: The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years, and safety, as measured by the occurrence of serious adverse events.
Related Papers (5)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 -